.bp-tirzepatide, .bp-tirzepatide * { box-sizing:border-box } .bp-tirzepatide .wrap{max-width:1040px;margin:0 auto;padding:22px 14px} .bp-tirzepatide h1{font-size:clamp(24px,3.8vw,36px);letter-spacing:-.02em;margin:0 0 8px} .bp-tirzepatide h2{font-size:clamp(18px,3.2vw,26px);margin:18px 0 8px} .bp-tirzepatide h3{font-size:clamp(16px,2.6vw,20px);margin:14px 0 6px} .bp-tirzepatide .lede{font-size:clamp(14px,2.2vw,17px);color:var(--muted);margin:4px 0 12px} .bp-tirzepatide .grid{display:grid;gap:12px} .bp-tirzepatide .cols{grid-template-columns:repeat(auto-fit,minmax(200px,1fr))} .bp-tirzepatide .card{border:1px solid var(--line);border-radius:12px;padding:14px;background:#fff;min-width:0} .bp-tirzepatide .chip{display:inline-block;background:rgba(15,98,254,.08);color:var(--brand);border:1px solid rgba(15,98,254,.25);font-size:12px;padding:4px 8px;border-radius:999px} .bp-tirzepatide .kbd{font-family:ui-monospace,Menlo,Consolas,monospace;background:#F6F7FA;border:1px solid #ECEEF3;border-radius:6px;padding:2px 6px;font-size:12px} .bp-tirzepatide p,.bp-tirzepatide li,.bp-tirzepatide .kbd,.bp-tirzepatide .chip{overflow-wrap:anywhere;word-break:break-word} .bp-tirzepatide ul{padding-left:18px;margin:8px 0} .bp-tirzepatide a{color:var(--brand);text-decoration:none;border-bottom:1px dashed rgba(15,98,254,.35)} .bp-tirzepatide a:hover{border-bottom-color:transparent} details.bp-acc{border:1px solid var(--line);border-radius:12px;padding:12px;background:#fff} details.bp-acc > *:not(summary){margin-top:8px} summary{cursor:pointer;font-weight:600} @media (max-width:420px){.bp-tirzepatide .wrap{padding:16px 12px}.bp-tirzepatide .card{padding:12px}} Tirzepatide — Dual Incretin (GLP-1 + GIP) Receptor Agonist Tirzepatide is a long-acting peptide that activates both the GLP-1 and GIP receptors. In research, it’s used to study how dual-incretin signaling influences glucose control, appetite pathways, and body-composition trends beyond what single-pathway GLP-1 analogues show. Identifiers CAS: 2023788-19-2 Peptide class: Long-acting incretin analogue (dual GLP-1/GIP) Approx. MW: ~4.8 kDa (sequence/salt form dependent) Design: Modified incretin sequence with a fatty-diacid side chain for albumin binding (extended half-life) How It Works (Plain English) GLP-1 receptor: supports insulin release, slows gastric emptying, and promotes a natural sense of fullness. GIP receptor: complements GLP-1 by modulating insulin secretion and adipose signaling in a context-dependent way. Together: Dual activation lets researchers observe broader metabolic effects than with GLP-1 alone, including changes in energy intake and fat distribution. Why Researchers Use It To compare dual-pathway vs single-pathway incretin signaling. To examine glucose tolerance, appetite regulation, and lipid markers. To explore body-composition shifts (including visceral fat) over longer time frames. Key Studies — What Was Tested, What Changed, Why It Matters Glucose control and insulin dynamics What was tested: Time-course effects on fasting and post-meal glucose, insulin secretion, and insulin sensitivity. What changed: Smoother glucose curves and stronger post-meal insulin responses vs baseline models; fewer high spikes after feeding. Why it matters: Shows how dual-incretin signaling can reduce metabolic “turbulence,” a useful setup for pancreatic-cell and whole-body glucose-handling studies. Appetite, gastric emptying, and energy intake What was tested: Central/peripheral signaling related to satiety, meal size, and gastric emptying rate. What changed: Reduced caloric intake, slower gastric emptying, and activation of appetite-regulating centers (brainstem/hypothalamus) in line with incretin biology. Why it matters: Offers a clear model for the brain–gut axis and how it shapes eating behavior and energy balance. Body-composition and lipid profiles What was tested: Changes in fat/lean mass and circulating lipids during sustained dual-incretin exposure. What changed: Trends toward visceral fat reduction, improved triglycerides, and healthier lipid fractions over time. Why it matters: Helps parse how incretin signaling affects where fat is stored—not just how much—an important distinction in metabolic risk models. Potential Research Applications Metabolic Function Glucose tolerance, insulin-secretion assays β-cell function and incretin cross-talk Appetite & Satiety Neuroendocrine signaling and meal-size control Gastric-emptying kinetics and gut–brain pathways Body-Composition Research Visceral vs subcutaneous adiposity (CT/MRI/DEXA) Lipid panels and metabolic flexibility Synergistic Peptides (for Study Design) Semaglutide (GLP-1) Why pair/compare: Establishes the added value of dual vs single incretin signaling. Angle: Side-by-side insulin, appetite, and imaging endpoints. AOD-9604 Why pair: Used in fat-metabolism research; complements incretin pathways from a different mechanism. Angle: Adipose and mitochondrial markers under combined stimuli. CJC-1295 (with DAC) Why pair: Probes cross-talk between GH/IGF-1 and incretin axes. Angle: Long-duration metabolic studies tracking glucose + lipid panels. Design Notes Define arms clearly: GLP-1 only, dual incretin, and combo with endocrine tools. Control for feeding schedule, stress, and activity—these shift outcomes. Document formulation (pH, light exposure) and storage rigorously. Known Concerns (Context) GI tolerance: Nausea and slower gastric emptying are common observations in incretin research; titration and timing matter. Model sensitivity: Appetite and glucose results can swing with environment; standardize meals, time of day, and stressors. General: Research use only; not for human consumption or therapeutic use. Follow institutional SOPs for incretin-pathway peptides and metabolic sampling schedules. Specifications & Handling Form: Lyophilized powder (lot-coded) Purity: ≥ 99% (HPLC/MS verified) Storage: ≤ −20 °C; protect from light/moisture In solution: Aliquot promptly; avoid repeat freeze–thaw Additives: None unless specified per lot Packaging: Tamper-evident; research-only labeling Regulatory & Use Notice Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance. Tirzepatide Peptide Research | Dual Incretin (GLP-1 + GIP) Agonist | Metabolic & Appetite Studies Keywords: Tirzepatide peptide, dual incretin, GLP-1 GIP agonist, appetite regulation, glucose control, visceral fat research, metabolic science, Base Peptides.